================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8 - K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (D)
Of the
SECURITIES EXCHANGE ACT OF 1934
Date of Report: MAY 21, 2003
ENDOVASC, INC.
(Exact name of registrant as specified in its charter)
NEVADA
(State or other jurisdiction of incorporation or organization)
000-28371 76-0512500
(Commission File Number) (IRS Employer Identification Number)
DR. DAVID P. SUMMERS, CHAIRMAN & CEO
ENDOVASC, INC.
550 CLUB DRIVE, SUITE 440
MONTGOMERY, TEXAS 77316
(Address of principal executive offices)
(936) 582-5920
(Registrant's telephone number, including area code)
15001 WALDEN RD., SUITE 108
MONTGOMERY, TEXAS 77356
(936) 448-2222
(Former name or former address and telephone number, if changed since last
report)
================================================================================
ITEM 5. OTHER EVENTS
- --------------------
On May 13, 2003 Endovasc, Inc.'s (EVSC), board of directors received
notification from MIV Therapeutics Inc. (MIV) that MIV would not be extending
its licensing agreement dated May 17, 2002 for the next year. All license fees
previously due before the cancellation have been paid in full.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ENDOVASC, INC.
(A NEVADA CORPORATION)
By:___________________________________________
Dr. David P. Summers, President and Chief
Executive Officer
DATE: MAY 20, 2003